NFlection Therapeutics Seeking Adult Participants for Clinical Trial on Cutaneous Neurofibromas (cNFs)

Author: NFlection Therapeutics
Published On: 11/18/2021

NFlection Therapeutics, Inc., a clinical-stage biopharmaceutical company, is currently recruiting adult patients for NFX-179 for the treatment of cutaneous neurofibromas. NFX-179 is a topical, first-in-class, “soft” MEK inhibitor that is currently being evaluated in Phase 2 clinical trials in patients with NF1. 

Volunteers, aged 18 years and older, are wanted for a clinical research study using an investigational topical medication. Patients must have a clinical diagnosis of NF1 and must have 10 or more cutaneous neurofibromas on their skin. During this study, all participants are seen by a board-certified dermatologist. There are no cost study-related evaluations and qualified participants will be reimbursed for time and travel. 

To learn more about NFX-179 and to find available clinic sites, visit the page here. Host sites are listed at the bottom of the page under "Contacts and Locations." 


Anyone considering participating in a clinical trial should discuss the matter with his or her physician. If you or a loved one is interested in participating in NF research, please read our clinical trials brochure to learn more about the clinical trial process and what that entails. 

Want to view archived newsletters? Click Here!


Sign up to receive the latest neurofibromatosis news and information in your inbox!



Have a story you'd like to share with the NF community? Click Here!